Cargando…

Tp53 disruptions: is there a marker of poor prognosis in chronic lymphoproliferative disorders?

Detalles Bibliográficos
Autores principales:	Cencini, Emanuele, Fabbri, Alberto, Raspadori, Donatella, Gozzetti, Alessandro, Bocchia, Monica
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis 2021
Materias:	Letters to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8721443/ https://www.ncbi.nlm.nih.gov/pubmed/34743076 http://dx.doi.org/10.5045/br.2021.2020322

Ejemplares similares

Drug resistance and minimal residual disease in multiple myeloma
por: Gozzetti, Alessandro, et al.
Publicado: (2022)

A BRAF-Negative Classic Hairy Cell Leukemia Patient with Long-Lasting Complete Remission after Rituximab and Pentostatin
por: Gozzetti, Alessandro, et al.
Publicado: (2020)

Long-Term Safety of Rapid Daratumumab Infusions in Multiple Myeloma Patients
por: Gozzetti, Alessandro, et al.
Publicado: (2020)

The Role of Tumor-Associated Macrophages in Hematologic Malignancies
por: Cencini, Emanuele, et al.
Publicado: (2021)

Venetoclax in association with decitabine as effective bridge to transplant in a case of relapsed early T‐cell lymphoblastic leukemia
por: Zappone, Elisabetta, et al.
Publicado: (2020)

Tumor-Associated Macrophages in Multiple Myeloma: Key Role in Disease Biology and Potential Therapeutic Implications
por: Cencini, Emanuele, et al.
Publicado: (2023)

“Friends and foes” of multiple myeloma measurable/minimal residual disease evaluation by next generation flow
por: Pacelli, Paola, et al.
Publicado: (2022)

Primary CNS lymphoma: latest updates and a 10-year monocenter experience
por: Cencini, Emanuele, et al.
Publicado: (2018)

Anti CD38 monoclonal antibodies for multiple myeloma treatment
por: Gozzetti, Alessandro, et al.
Publicado: (2022)

Minimal Residual Disease in Multiple Myeloma: State of the Art and Applications in Clinical Practice
por: Gozzetti, Alessandro, et al.
Publicado: (2020)

Role of lenalidomide in the treatment of peripheral T-cell non-Hodgkin lymphomas
por: Cencini, Emanuele, et al.
Publicado: (2021)

Lenalidomide and Temozolomide Combination in a Very Elderly Patient with CNS Relapse of Diffuse Large B-Cell Lymphoma
por: Cencini, Emanuele, et al.
Publicado: (2017)

CD26/DPP-4 in Chronic Myeloid Leukemia
por: Sicuranza, Anna, et al.
Publicado: (2022)

Identification of a Novel P190-Derived Breakpoint Peptide Suitable for Peptide Vaccine Therapeutic Approach in Ph+ Acute Lymphoblastic Leukemia Patients
por: Ippoliti, Micaela, et al.
Publicado: (2012)

Steps towards a Multiple Myeloma Cure?
por: Gozzetti, Alessandro, et al.
Publicado: (2022)

Liquid biopsy and blood-based minimal residual disease evaluation in multiple myeloma
por: GOZZETTI, ALESSANDRO, et al.
Publicado: (2023)

Wild-Type TP53 Predicts Poor Prognosis in Patients with Gastric Cancer
por: Deng, Wenhong, et al.
Publicado: (2021)

Genetic alterations of KRAS and TP53 in intrahepatic cholangiocarcinoma associated with poor prognosis
por: Peng, Jianbo, et al.
Publicado: (2023)

TP53 and TP53-associated genes are correlated with the prognosis of paediatric neuroblastoma
por: Wang, Haiwei, et al.
Publicado: (2022)

S127: DELTATP73 IMPOSES TP53 MUTANT-LIKE PHENOTYPES INCLUDING DRUG RESISTANCE AND POOR PROGNOSIS ON TP53-WILD TYPE ACUTE MYELOID LEUKEMIA.
por: Pereira-Martins, Diego A, et al.
Publicado: (2023)

The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19
por: Gozzetti, Alessandro, et al.
Publicado: (2020)

Daratumumab efficacy in extramedullary orbital myeloma
por: Gozzetti, Alessandro, et al.
Publicado: (2020)

TP53 R273C Mutation Is Associated With Poor Prognosis in LGG Patients
por: Zhang, Jian, et al.
Publicado: (2022)

The clinical characteristics and prognosis in adult Ph negative acute lymphoblastic leukemia with TP53 aberrations
por: Fang, Qiuyun, et al.
Publicado: (2022)

STAT3 and TP53 mutations associate with poor prognosis in anaplastic large cell lymphoma
por: Lobello, Cosimo, et al.
Publicado: (2020)

TP53 Mutation Infers a Poor Prognosis and Is Correlated to Immunocytes Infiltration in Breast Cancer
por: Zhang, Ziwen, et al.
Publicado: (2021)

The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis
por: Leroy, Bernard, et al.
Publicado: (2013)

Alterations of TP53 in microdissected transitional cell carcinoma of the human urinary bladder: high frequency of TP53 accumulation in the absence of detected mutations is associated with poor prognosis.
por: Abdel-Fattah, R., et al.
Publicado: (1998)

Therapeutic Advancements in Multiple Myeloma
por: Gozzetti, Alessandro, et al.
Publicado: (2014)

Telomere status in chronic lymphocytic leukemia with TP53 disruption
por: Guièze, Romain, et al.
Publicado: (2016)

Overexpression of RBBP6, Alone or Combined with Mutant TP53, Is Predictive of Poor Prognosis in Colon Cancer
por: Chen, Jian, et al.
Publicado: (2013)

TP53 Mutation Related and Directly Regulated lncRNA Prognosis Markers in Hepatocellular Carcinoma
por: Zhang, Xiulei, et al.
Publicado: (2021)

Impact of TP53 mutations in breast cancer: Clinicopathological features and prognosisImpact of TP53 mutations in breast CA
por: Li, Xuerui, et al.
Publicado: (2020)

TP53 mutation predicts the poor prognosis of non-Hodgkin lymphomas: Evidence from a meta-analysis
por: Xu, Peipei, et al.
Publicado: (2017)

TP53 mutation variant allele frequency of ≥10% is associated with poor prognosis in therapy-related myeloid neoplasms
por: Shah, Mithun Vinod, et al.
Publicado: (2023)

A case of bone lesion in a patient with relapsed chronic lymphocytic leukemia and review of the literature
por: Bacchiarri, Francesca, et al.
Publicado: (2022)

Mitigating the Risk of t-MNs Development: TP53 or Not TP53?
por: Tesio, Melania
Publicado: (2023)

CSNK1E/CTNNB1 Are Synthetic Lethal To TP53 in Colorectal Cancer and Are Markers for Prognosis
por: Tiong, Khong-Loon, et al.
Publicado: (2014)

TP53 Mutations Identified Using NGS Comprise the Overwhelming Majority of TP53 Disruptions in CLL: Results From a Multicentre Study
por: Catherwood, Mark A., et al.
Publicado: (2022)

Obinutuzumab plus chlorambucil versus ibrutinib in previously untreated chronic lymphocytic leukemia patients without TP53 disruptions: A real-life CLL campus study
por: Visentin, Andrea, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_q4qe29ajj0sukvq7gr3qj6sg3p